BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33409897)

  • 1. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
    Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
    Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
    Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
    J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
    Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
    Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
    Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
    Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
    Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
    PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
    Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
    Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
    Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
    Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes
    Sootome H; Miura A; Masuko N; Suzuki T; Uto Y; Hirai H
    Mol Cancer Ther; 2020 Oct; 19(10):1981-1991. PubMed ID: 32788206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
    Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
    Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 20. Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.
    Silva A; Wang J; Lomahan S; Tran TA; Grenlin L; Suganami A; Tamura Y; Ikegaki N
    Oncol Rep; 2014 Sep; 32(3):901-5. PubMed ID: 25017515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.